Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with ...

(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

In its Friday approval letter, the FDA didn’t explain the restrictions although they reflect skepticism about ...

The Nuvaxovid COVID-19 vaccine was developed in cooperation with Sanofi, which will pay Novavax $175 million in a milestone agreement. Novavax received Food and Drug Administration approval for its ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

Health agencies working under Robert F. Kennedy Jr. are making changes to the nation's decades-old system for approving and ...

JN.1 may not be more severe, but it spreads fast, and that’s reason enough to stay alert. Across Asia, the priority is clear: ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

The vaccine will only be available to those at high risk from COVID—excluding those who may need it to protect a relative or ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...